Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 62,898 | 54,116 | 41,374 | 45,059 | 37,095 |
| Cost of Goods | 1,626 | 2,061 | 1,504 | 4,564 | 1,289 |
| Gross Profit | 61,272 | 52,055 | 39,870 | 40,495 | 35,806 |
| Operating Expenses | 118,047 | 119,820 | 179,611 | 135,292 | 128,680 |
| Operating Income | -56,149 | -67,704 | -139,237 | -94,233 | -92,585 |
| Interest Expense | 2,777 | 2,788 | 2,800 | 2,820 | 2,821 |
| Other Income | 4,090 | 925 | 6,270 | 8,525 | 6,177 |
| Pre-tax Income | -54,836 | -69,567 | -135,767 | -88,528 | -89,229 |
| Income Tax | -84 | 85 | 191 | 68 | 12 |
| Net Income Continuous | -54,752 | -69,652 | -135,958 | -88,596 | -89,241 |
| Net Income Discontinuous | -59 | -757 | -103 | -1,577 | 239,976 |
| Net Income | $-54,811 | $-70,409 | $-136,061 | $-90,173 | $150,735 |
| EPS Basic Total Ops | -0.70 | -0.91 | -1.76 | -1.07 | 1.97 |
| EPS Basic Continuous Ops | -0.70 | -0.90 | -1.76 | -1.14 | -1.17 |
| EPS Basic Discontinuous Ops | 0.00 | -0.01 | 0.00 | 0.07 | 3.14 |
| EPS Diluted Total Ops | -0.70 | -0.91 | -1.76 | -1.07 | 1.97 |
| EPS Diluted Continuous Ops | -0.70 | -0.90 | -1.76 | -1.14 | -1.17 |
| EPS Diluted Discontinuous Ops | 0.00 | -0.01 | 0.00 | 0.07 | 3.14 |
| EPS Diluted Before Non-Recurring Items | -0.70 | -0.90 | -1.76 | N/A | N/A |
| EBITDA(a) | $-44,910 | $-57,359 | $-129,357 | $-90,483 | $-81,110 |